Novo Nordisk signed a $1.3 billion deal for technology to make longer-lasting obesity shots
- Novo Nordisk: 14 events in the last 90 days
- Previous: 2 days earlier · U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast
What happened
The agreement gives Novo exclusive rights to Swedish startup Nanexa's drug-coating technology for up to 5 programs targeting obesity and diabetes
Summary assembled by rule from the sources below